The mortality of colorectal cancer continues to stagnate despite the development of new therapeutic approaches. Therefore, identifying high-risk population groups could contribute to the prevention of a considerable part of deaths caused by colorectal tumors.
Methods
Fifty patients with colon cancer and 50 patients with other, nonmalignant diseases were selected for the study. Expression of the c-myc, Ha-ras and p53 genes was determined in the peripheral leukocytes of the participants.
Results
Marked elevations of the expression of all three investigated genes were seen in the colon cancer patients when compared to the controls.
Conclusions
Our investigations showed that increases in the expression of c-myc, Ha-ras and p53 genes can be demonstrated in the peripheral leukocytes of colon cancer patients. By applying our method to clinical investigations, individuals with a high risk of having developed colon cancer may be identified and early diagnosis may be established.
LakatosP., LakatosL.: Current concepts in the genetics of hereditary and sporadic colorectal cancer and the role of genetics in patient management. Orv Hetil, 147: 363–368, 2006.
3.
FriedmanE., IsakssonP., RafterJ., MarianB., WinawerS., NewmarkH.: Fecal diglycerides as selective endogenous mitogens for premalignant and malignant human colonic epithelial cells. Cancer Res, 49: 544–548, 1989.
4.
NairP.P.: Role of bile acids and neutral steroids in carcinogenesis. Am J Clin Nutr, 48: 768–774, 1988.
5.
FitzerC.J., O'BrianC.A., GuillemJ.G., WeinsteinI.B.: The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several related bile acids. Carcinogenesis, 8: 217–220, 1987.
6.
GuillemJ.G., O'BrianC.A., FitzerC.J., JohnsonM.D., FordeK.A., LoGerfoP., WeinsteinI.B.: Studies on protein kinase C and colon carcinogenesis. Arch Surg, 122: 1475–1478, 1987.
7.
PajkosG., KissI., SándorJ., EmberI., KisháziP.: The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res, 20: 1695–1701, 2000.
8.
MolatoreS., RanzaniG.N.: Genetics of colorectal cancer. Tech Coloproctol,8: S240–S242, 2004.
9.
HoflerH.: Oncogene expression in colonic cancers. Wien Med Wochenschr, 138: 271–273, 1988.
10.
LundyJ., ChenJ., WangP., FromowitzF., SchussA., LynchS., BruggeJ., ViolaM.V.: Phenotypic and genetic alterations in pre-cancerous cells in the colon. Anticancer Res, 8: 1005–1013, 1988.
11.
AstrinS.M.: Are there molecular targets for therapy of colon cancer?Oncology,5: 127–132, 1991.
12.
AhnenD.J.: Genetics of colon cancer. West J Med, 154: 700–705, 1991.
13.
BalmainA., BrownK., AkhurstR.K., FeeF.M.: Molecular analysis of chemical carcinogenesis in the skin. Cell, 46: 72–75, 1988.
14.
BosJ.L.: Ras oncogenes in human cancer: A review. Cancer Res, 49: 4682–4689, 1987.
15.
GyöngyiZ., EmberI., KissI., VargaC.: Changes in expression of onco- and suppressor genes in peripheral leukocytes as potential biomarkers of chemical carcinogenesis. Anticancer Res, 21: 3377–3380, 2001.
16.
GyöngyiZ., NádasiE., VargaC., KissI., EmberI.: Long-term effects of 1-nitropyrene on oncogene and tumor suppressor gene expression. Anticancer Res, 21: 3937–3940, 2001.
17.
EmberI., KissI., GombkötoG., MüllerE., SzeremiM.: Oncogene and suppressor gene expression as a biomarker for ethylene oxide exposure. Cancer Detect Prev, 22: 241–245, 1998.
18.
KussieP.H., GorinaS., MarechalV., ElenbaasB., MoreauJ., LevineA.J., PavletichN.P.: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274: 948–953, 1996.
19.
GervazP., BucherP., MorelP.: Two colons - two cancers: paradigm shift and clinical implications. J Surg Oncol, 88: 261–266, 2004.
20.
EmberI., KissI., RaposaT.: The usefulness of in vivo gene expression investigations from peripheral white blood cells: a preliminary study. Eur J Cancer Prev, 8: 331–334, 1999.
21.
EmberI., KissI., FaluhelyiZ.: Gene expression changes as potential biomarkers of tumour bearing status in humans. Eur J Cancer Prev, 7: 347–348, 1998.
22.
KlatkaJ., RolinskiJ., KupiszK., KlonowskiS., SkomraD.: Expression of bcl-2 protein in lymphocytes of patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol, 256: 299–302, 1999.
23.
LundinC., MertensF.: Cytogenetics of benign breast lesions. Breast Cancer Res Treat, 51: 1–15, 1998.
24.
RossA.A., CooperB.W., LazarusH.M., MackayW., MossT.J., CiobanuN., TallmanM.S., KennedyM.J., DavidsonN.E., SweetD., WinterC., AkardL., JansenJ., CopelanE., MeagherR.C., HerzingR.H., KlumppT.R., KahnD.G., WarnerN.E.: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood, 82: 2605–2610, 1993
25.
SolmiR., UgoliniG., RosatiG., ZanottiM.L., MontriniI., del GovernatoreM., CairaA., TaffurelliM., SantiniD., CoppolaD., GuidottiL., CarinciP., StrippoliP.: Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer, 6: 250, 2006.
26.
BishopJ.M.: The molecular genetics of cancer. Science, 235: 305–311, 1987.
27.
FearonE.R., VogelsteinB.: A genetic model of colorectal tumorigenesis. Cell, 61: 759–767, 1991.
